OSI-930
- Generic Name
- OSI-930
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H16F3N3O2S
- CAS Number
- 728033-96-3
- Unique Ingredient Identifier
- G1PEG5Q9Y2
- Background
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers.
- Indication
Investigated for use/treatment in solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Phase 1 Study of OSI-930 in Cancer Patients
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00513851
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇬🇧Cancer Research UK Professor of Medical Oncology, Sutton, Surrey, United Kingdom
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.